Harpreet Singh‐Jasuja

6.2k citations

30 papers · 2.4k indexed · h-index 20

Immunology top 1%
Molecular Biology top 10%
Oncology top 5%
Epidemiology top 10%
Cell Biology top 10%

Co-authors: Hans‐Georg Rammensee Norbert Hilf Hansjörg Schild René E. M. Toes Danièle Arnold-Schild Hans Ulrich Scherer Steffen Walter Hans-Georg Rammensee
Topics: Immunotherapy and Immune Responses (25 papers)Cancer Immunotherapy and Biomarkers (9 papers)vaccines and immunoinformatics approaches (8 papers)
Cited by: Immunology Oncology Molecular Biology
Journals: Journal of Biological Chemistry The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: Germany United Kingdom Switzerland

In The Last Decade

Harpreet Singh‐Jasuja

28 papers receiving 2.4k citations

Peers

Countries citing papers authored by Harpreet Singh‐Jasuja

Since Specialization

Citations

This map shows the geographic impact of Harpreet Singh‐Jasuja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harpreet Singh‐Jasuja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harpreet Singh‐Jasuja more than expected).

Fields of papers citing papers by Harpreet Singh‐Jasuja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harpreet Singh‐Jasuja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harpreet Singh‐Jasuja. The network helps show where Harpreet Singh‐Jasuja may publish in the future.

Co-authorship network of co-authors of Harpreet Singh‐Jasuja

This figure shows the co-authorship network connecting the top 25 collaborators of Harpreet Singh‐Jasuja. A scholar is included among the top collaborators of Harpreet Singh‐Jasuja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harpreet Singh‐Jasuja. Harpreet Singh‐Jasuja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules 2019 ·Blood ·Sebastian Bunk,Martin Hofmann,Felix Unverdorben,Meike Hutt,(unknown),(unknown),Claudia Wagner,Sara Yousef,Heiko Schuster,(unknown),Oliver Schoor,Toni Weinschenk,Harpreet Singh‐Jasuja,Dominik Maurer,Carsten Reinhardt	7
2	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA 2018 ·Neuro-Oncology ·Wolfgang Wick,Pierre‐Yves Dietrich,Norbert Hilf,Michael Platten,Katrin Frenzel,Arie Admon,Sjoerd van der Burg,Andreas von Deimling,Cécile Gouttefangeas,Judith R. Kroep,Francisco Martínez‐Ricarte,Hideho Okada,Christian H. Ottensmeier,Berta Ponsati,Hans Skovgaard Poulsen,Stefan Stevanović,Ghazaleh Tabatabai,Hans‐Georg Rammensee,Uğur Şahin,Harpreet Singh‐Jasuja	1
3	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases 2017 ·European Urology Focus ·Steffen Rausch,Cécile Gouttefangeas,Jörg Hennenlotter,(unknown),Kerstin Walter,Susan Feyerabend,(unknown),Stephan Kruck,Harpreet Singh‐Jasuja,(unknown),(unknown),Stefan Stevanović,Arnulf Stenzl,Hans‐Georg Rammensee,Jens Bedke	19
4	A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma 2016 ·Clinical Cancer Research ·R. Rampling,(unknown),Paul Mulholland,Allan James,(unknown),Christopher Twelves,Catherine McBain,Sarah Jefferies,Alan Jackson,William Stewart,Juha Lindner,(unknown),Norbert Hilf,(unknown),(unknown),(unknown),Oliver Schoor,Harpreet Singh‐Jasuja,Sarah Halford,(unknown)	122
5	Final Results from a Cancer Research Uk First in Man Phase I Trial of Ima950 (A Novel Multi Peptide Vaccine) Plus Gm-Csf in Patients with Newly Diagnosed Glioblastoma 2014 ·Annals of Oncology ·Sarah Halford,R. Rampling,Allan James,(unknown),Paul Mulholland,(unknown),Chris Twelves,Catherine McBain,Sarah Jefferies,(unknown),Norbert Hilf,(unknown),Jurriaan M. Peters,(unknown),Oliver Schoor,(unknown),Harpreet Singh‐Jasuja	7
6	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy 2013 ·World Journal of Urology ·Jens Bedke,Cécile Gouttefangeas,Harpreet Singh‐Jasuja,Stefan Stevanović,(unknown),Arnulf Stenzl	25
7	HLA ligandome tumor antigen discovery for personalized vaccine approach 2013 ·Expert Review of Vaccines ·Hans‐Georg Rammensee,Harpreet Singh‐Jasuja	74
8	Abstract 3971: Impact of various first- and second-generation tyrosine-kinase inhibitors on frequency and functionality of immune cells. 2013 ·Cancer Research ·Nina N. Pawlowski,(unknown),Harpreet Singh‐Jasuja,Norbert Hilf	1
9	Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901 2012 ·OncoImmunology ·Steffen Walter,Toni Weinschenk,Carsten Reinhardt,Harpreet Singh‐Jasuja	32
10	Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy 2012 ·Brain ·Valérie Dutoit,Christel Herold‐Mende,Norbert Hilf,Oliver Schoor,Philipp Beckhove,(unknown),(unknown),(unknown),Jens Fritsche,(unknown),Jennifer Lohr,Hans‐Georg Rammensee,Stefan Stevanović,Claudia Trautwein,Verona Vass,Steffen Walter,Paul R. Walker,Toni Weinschenk,Harpreet Singh‐Jasuja,Pierre‐Yves Dietrich	146
11	Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma 2012 ·Cancer Immunology Immunotherapy ·Jürgen C. Becker,Mads Hald Andersen,(unknown),Marion Wobser,(unknown),(unknown),Steffen Walter,Harpreet Singh‐Jasuja,Eckhart Kämpgen,Andreas Opitz,Marc Zapatka,Eva‐B. Bröcker,Per thor Straten,David Schrama,Selma Ugurel	60
12	Nucleosome, the Main Autoantigen in Systemic Lupus Erythematosus, Induces Direct Dendritic Cell Activation via a MyD88-Independent Pathway: Consequences on Inflammation 2005 ·The Journal of Immunology ·Patrice Decker,Harpreet Singh‐Jasuja,(unknown),Ina Kötter,Hans‐Georg Rammensee	91
13	Glycoprotein 96–activated dendritic cells induce a CD8-biased T cell response 2005 ·Cell Stress and Chaperones ·(unknown),Harpreet Singh‐Jasuja,Tobias Warger,(unknown),Norbert Hilf,(unknown),Hans‐Georg Rammensee,Hansjörg Schild	32
14	Multiple synergizing factors contribute to the strength of the CD8+ T cell response against listeriolysin O 2005 ·International Immunology ·Dunja Bruder,Alexander K. Nussbaum,(unknown),Markus Schirle,Stefan Stevanović,Harpreet Singh‐Jasuja,Ayub Darji,Trinad Chakraborty,Hansjörg Schild,Israel Pecht,Siegfried Weiß	7
15	The T�bingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy 2004 ·Cancer Immunology Immunotherapy ·Harpreet Singh‐Jasuja,Niels Emmerich,Hans‐Georg Rammensee	101
16	The heat shock protein Gp96 links innate and specific immunity 2002 ·International Journal of Hyperthermia ·Norbert Hilf,Harpreet Singh‐Jasuja,Hansjörg Schild	18
17	The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway 2002 ·Journal of Biological Chemistry ·R. Martin Vabulas,(unknown),Norbert Hilf,Harpreet Singh‐Jasuja,Sylvia Herter,Parviz Ahmad‐Nejad,Carsten J. Kirschning,(unknown),Hans‐Georg Rammensee,Hermann Wagner,Hansjörg Schild	378
18	Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein 2002 ·European Journal of Immunology ·S. Welte,Christian Sinzger,Stefan Lutz,Harpreet Singh‐Jasuja,Kerstin Laib Sampaio,(unknown),Hans‐Georg Rammensee,Alexander Steinle	195
19	The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells 2000 ·Cell Stress and Chaperones ·Harpreet Singh‐Jasuja,Norbert Hilf,Hans Ulrich Scherer,Danièle Arnold-Schild,Hans‐Georg Rammensee,René E. M. Toes,Hansjörg Schild	63
20	The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor 2000 ·European Journal of Immunology ·Harpreet Singh‐Jasuja,Hans Ulrich Scherer,Norbert Hilf,Danièle Arnold-Schild,Hans-Georg Rammensee,René E. M. Toes,Hansjörg Schild	292

About Harpreet Singh‐Jasuja

Harpreet Singh‐Jasuja is a scholar working on Immunology, Oncology and Molecular Biology, having authored 30 papers that have together received 2.4k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (25 papers), Cancer Immunotherapy and Biomarkers (9 papers) and vaccines and immunoinformatics approaches (8 papers). The work is most often cited by research in Immunology (1.7k citations), Oncology (687 citations) and Molecular Biology (1.1k citations). Harpreet Singh‐Jasuja has collaborated with scholars based in Germany, United Kingdom and Switzerland. Frequent co-authors include Hans‐Georg Rammensee, Norbert Hilf, Hansjörg Schild, René E. M. Toes, Danièle Arnold-Schild, Hans Ulrich Scherer, Steffen Walter, Hans-Georg Rammensee, Toni Weinschenk and Hermann Wagner. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact